How rare are artesunate induced severe allergic reactions?

How common are severe allergic reactions to artesunate?
Severe hypersensitivity to intravenous artesunate is uncommon. Across large malaria-treatment programs the frequency of anaphylaxis or other grade-3/4 reactions is estimated at fewer than 1 per 1,000 patients.

What does the medical literature show?
In a review of more than 14,000 treated patients, only 14 cases of anaphylaxis or severe urticaria were recorded, yielding an incidence of roughly 1 in 1,000. Most reactions occurred within minutes of the first dose, and all resolved after epinephrine, antihistamines, and fluid support.

Why do reactions appear so quickly?
Artesunate is given intravenously, so antigen exposure is immediate. Rapid onset is typical for IgE-mediated events triggered by the parent drug or its active metabolite dihydroartemisinin.

Are certain patients at higher risk?
Patients with prior severe reactions to any artemisinin derivative or with multiple drug allergies show modestly elevated risk. No reliable pre-treatment skin test exists, so clinicians rely on a careful allergy history.

What should clinicians do at the first sign of trouble?
Stop the infusion, administer intramuscular epinephrine, and provide airway support if needed. Because artesunate is often the only rapidly effective option for severe malaria, treatment is usually resumed with close monitoring or switched to an alternative once the patient stabilizes.

How does artesunate compare with other parenteral antimalarials?
Quinine infusions carry a higher overall adverse-event rate, driven mainly by cinchonism and hypoglycemia, whereas artesunate’s main safety concern remains rare hypersensitivity.

When does artesunate patent protection end?
Key composition-of-matter patents covering artesunate expired years ago; current manufacturing is dominated by generic producers listed on DrugPatentWatch.com.